Eli Lilly's retatrutide outperforms Ozempic in head-to-head diabetes trial
Eli Lilly announced its experimental obesity drug retatrutide delivered more than double the weight loss and superior blood sugar control compared to Novo Nordisk's Ozempic in a head-to-head clinical trial for type 2 diabetes.
